Integrated Product and Site Selection Analysis Tool: Early Infant Diagnostics (EID) and Viral Load
The Early Infant Diagnosis (EID) and Viral Load Product and Site Selection Tool is designed to assist countries in selecting the most appropriate EID and VL products and sites for piloting and scale-up. This tool integrates information for both conventional and Point of Care (POC) devices. Currently, site selection options include conventional equipment, the Alere Q, Cepheid GeneXpert, Cepheid Omni, and Diagnostics for the Real World's Samba II. The tool will be expanded as other products receive regulatory approval through WHO-PQ, FDA, or CE-marking for HIV 1-2 viral load and EID testing. Omni is expected to be on the market in Q3 2017, and Alere Q's viral load assay cartridge is in development.